Form 4: Longeveron Inc. Chief Medical Officer Reports Stock Transaction

Nataliya Agafonova, Chief Medical Officer of Longeveron Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Summary

• On October 1, 2024, Nataliya Agafonova, the Chief Medical Officer of Longeveron Inc., had 5,316 shares of Class A Common Stock withheld to satisfy tax obligations related to the vesting of a restricted stock unit award.
• The price per share was $1.88.
• Following the transaction, Agafonova beneficially owns 157,814 shares, which includes restricted stock units subject to future vesting.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, which is neutral to slightly positive as it indicates ongoing vesting of stock units. There is nothing in the document to suggest a negative outlook.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their stock transactions. It is a standard practice for officers of publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders in publicly traded companies, ensuring transparency in their stock transactions.
• Similar filings are common among executives at companies like BioNTech, Moderna, and other biotech firms, reflecting stock-based compensation and related tax obligations.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it involves the withholding of shares for tax purposes and does not represent a significant change in the executive's overall holdings.

Key Dates